Basic Knowledges of Disease and Role of Pharmacists in Pharmaceutical Care for Patient with Systemic Lupus Erythematosus (SLE)

Authors

  • Karunrat Tewthanom Silpakorn University
  • Surassawadee Suntharasaj Department of Pharmacy, Faculty of Pharmacy, Silpakorn University

Keywords:

drug related problems, SLE, treatment guideline, basic knowledges, role of pharmacist

Abstract

SLE is an immune disorder. The owner's organs or cells cannot be recognized. Causes the destruction of normal cells from immune reactions.  As a result, the organs Inflammation occurs and there is an irregular functioning. The cause of the disease is currently unknown, but genetics and environmental conditions such as heat, sunlight, virus, stress, and cigarette smoking can contribute to the disease or provoke relapses. Therefore, treatment is generally recommended to modify behavior in combination with taking medications.  the European Association for Joint Diseases. Hydroxychloroquine, glucocorticoids, immunosuppressants, and biopharmaceuticals are recommended as primary medications, so pharmacists should review treatment guidelines and play a role in patient care. To help with the problem of drug use, especially special groups of patients who have limitations on medication such as pregnant women or the elderly, take into account other dimensions, including psychological, social, as well as family planning, which are relevant factors and have an impact on the treatment of this disease.

Downloads

Download data is not yet available.

References

Jerika T. Lam, Ann M. Lynch, and Marry A. Gutierrez. 2018 "Systemic Lupus Erythematosus." In Applied Therapeutic and Clinical use of drugs, by Michael G Carvalho Caroline S Zeind. NY: Wolter Kulwer.

Beth H. Resmon-Targof. 2018. "Systemic Lupus Erythematosus." In Pharmacotherapy: a pathophysiological approach, by Robert L Tolbert, Gary C Yee, Gary R Matzke, Barbara G Wells, L Michael Posey Joseph T Dipiro, 2512. NY: McGraw-Hill.

Petri M. Treatment of Systemic Lupus Erythematosus: An Update. Am Fam Physician. 1998 Jun 1;57 (11):275327

Rao N, Kumar A, Kumari M. Systemic Lupus Erythematosus. Journal of Scientific Innovation. 2013;2(1):3-5.

Petri M, Orbai AM, Alacorn GS, et al. Deviation and Validation of Systemic lupus international Collaborating Clinic classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677-2686

Tan EM, Cohen AS, Fries F et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-1277

Hochibierg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;71(9):1400-1412.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Ricard Cervera, et. al 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78:736–745.

Vukelic M, Li Y, Kyttaris V. Novel Treatments in Lupus. Frontiers in Immunology. 2018;9.

Mosca M, Vollenhoven RV, New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S82- S85.

Touma Z, Gladman D D. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Science & Medicine 2017;4:e000239. doi:10.1136/lupus- 2017-000239

Gergianaki I Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Frontiers in Medicine. 2018;161:1-12

Konttinen Y, Santavirta N, Honkanen V, Sandelin S, Schauman L, Gronblad M. Systemic lupus erythematosus patient guide: influence on knowledge of the disease. Annals of the Rheumatic Diseases. 1991;50(12):900-902.

Xia Xie Hui Yang Aliu Nie Hong Chen Jiping Li, Predictors of medication nonadherence in patients with systemic lupus erythematosus in Sichuan: a cross-sectional study Patient Preference and Adherence 2018:12

Ganachari M, Almas S. Evaluation of clinical pharmacist mediated education and counseling of systemic lupus erythematosus patients in tertiary care hospital. Indian Journal of Rheumatology. 2012;7(1):7-12.

Nadja Maria Jorge Asano, Maria das Graças Wanderley de Sales Coriolano ,Breno Jorge Asano Otávio, Gomes Lins. Psychiatric comorbidities in patients with systemic lupus erythematosus: a systematic review of the last 10 years. Rev Brasreumatol. 2013; 53(5):431-437.

Figueiredo-Braga M, Cornaby C, Cortez A, Bernardes M, Terroso G, Figueiredo M, et. al. Depression and anxiety in systemic lupus erythematosus: The crosstalk between immunological, clinical, and psychosocial factors. Medicine 2018;97::1-11.

Conceição C, Meinão I, Bombana J, Sato E. Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial. Advances in Rheumatology. 2019;59(1).

Barr A, Badell M, Vettese T. Contraception Counseling in Patients With SLE and Other Chronic Medical Conditions Requiring Potentially Teratogenic Medications. JAMA Internal Medicine. 2019;179(4):562.

Lewkonia R. The Clinical Genetics of Lupus. Lupus. 1992;1(2):55-62.

Published

2022-09-06

How to Cite

Tewthanom, K., & Suntharasaj, S. . (2022). Basic Knowledges of Disease and Role of Pharmacists in Pharmaceutical Care for Patient with Systemic Lupus Erythematosus (SLE) . Hua Hin Medical Journal, 2(2), 43–57. Retrieved from https://he01.tci-thaijo.org/index.php/hhsk/article/view/254026

Issue

Section

Review article